Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from Pro Medicus Limited ( (AU:PME) ).
Pro Medicus Limited has reported a significant financial performance for the half-year ending December 2024, with a 31.1% increase in revenue from contracts with customers and a 42.9% rise in underlying profit before tax compared to the previous period. The reported profit before tax surged by 46.1%, and the net profit for the period attributable to members increased by 42.7%, showcasing the company’s strong operational growth. Additionally, the company announced an increase in its interim dividend to 25.0 cents per share, reflecting its robust financial health and commitment to returning value to its shareholders.
More about Pro Medicus Limited
Pro Medicus Limited operates in the healthcare technology industry, providing advanced imaging solutions and healthcare informatics services. Their primary products include radiology information systems, picture archiving and communication systems, and advanced visualization tools. The company focuses on enhancing medical imaging efficiency and accuracy, serving hospitals and healthcare providers globally.
YTD Price Performance: 12.77%
Average Trading Volume: 343
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $18.78B
For an in-depth examination of PME stock, go to TipRanks’ Stock Analysis page.
